CN103998053B9 - 通过抑制il-4和/或il-13与其各自的受体结合来预防或治疗某些障碍的方法 - Google Patents

通过抑制il-4和/或il-13与其各自的受体结合来预防或治疗某些障碍的方法 Download PDF

Info

Publication number
CN103998053B9
CN103998053B9 CN201280061754.7A CN201280061754A CN103998053B9 CN 103998053 B9 CN103998053 B9 CN 103998053B9 CN 201280061754 A CN201280061754 A CN 201280061754A CN 103998053 B9 CN103998053 B9 CN 103998053B9
Authority
CN
China
Prior art keywords
lipocalin
use according
pharmaceutical composition
human
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280061754.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN103998053A (zh
CN103998053B (zh
Inventor
安德里亚斯·霍尔鲍姆
劳伦·奥多利
贝弗莉·科勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pieris Pharmaceuticals GmbH
Bristol Myers Squibb Co
Original Assignee
Pieris AG
Pieris Pharmaceuticals GmbH
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris AG, Pieris Pharmaceuticals GmbH, Bristol Myers Squibb Co filed Critical Pieris AG
Priority to CN201811146540.5A priority Critical patent/CN109432402B/zh
Publication of CN103998053A publication Critical patent/CN103998053A/zh
Application granted granted Critical
Publication of CN103998053B publication Critical patent/CN103998053B/zh
Publication of CN103998053B9 publication Critical patent/CN103998053B9/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201280061754.7A 2011-12-13 2012-12-12 通过抑制il-4和/或il-13与其各自的受体结合来预防或治疗某些障碍的方法 Expired - Fee Related CN103998053B9 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811146540.5A CN109432402B (zh) 2011-12-13 2012-12-12 通过抑制il-4和/或il-13与其各自的受体结合来预防或治疗某些障碍的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161570018P 2011-12-13 2011-12-13
US61/570,018 2011-12-13
PCT/EP2012/075146 WO2013087660A1 (en) 2011-12-13 2012-12-12 Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201811146540.5A Division CN109432402B (zh) 2011-12-13 2012-12-12 通过抑制il-4和/或il-13与其各自的受体结合来预防或治疗某些障碍的方法

Publications (3)

Publication Number Publication Date
CN103998053A CN103998053A (zh) 2014-08-20
CN103998053B CN103998053B (zh) 2018-11-02
CN103998053B9 true CN103998053B9 (zh) 2020-07-21

Family

ID=47552959

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811146540.5A Expired - Fee Related CN109432402B (zh) 2011-12-13 2012-12-12 通过抑制il-4和/或il-13与其各自的受体结合来预防或治疗某些障碍的方法
CN201280061754.7A Expired - Fee Related CN103998053B9 (zh) 2011-12-13 2012-12-12 通过抑制il-4和/或il-13与其各自的受体结合来预防或治疗某些障碍的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201811146540.5A Expired - Fee Related CN109432402B (zh) 2011-12-13 2012-12-12 通过抑制il-4和/或il-13与其各自的受体结合来预防或治疗某些障碍的方法

Country Status (13)

Country Link
US (6) US9572863B2 (enExample)
EP (3) EP3453400B1 (enExample)
JP (5) JP6163162B2 (enExample)
CN (2) CN109432402B (enExample)
AU (1) AU2012350660B2 (enExample)
CA (1) CA2858962C (enExample)
DK (2) DK2790719T3 (enExample)
ES (2) ES2863410T3 (enExample)
HU (2) HUE042720T2 (enExample)
PL (2) PL2790719T3 (enExample)
SG (2) SG11201402992SA (enExample)
TR (1) TR201901826T4 (enExample)
WO (1) WO2013087660A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE043835T2 (hu) * 2010-06-08 2019-09-30 Pieris Pharmaceuticals Gmbh IL-4 receptor-alfát kötõ könny-lipokalin muteinek
CN109432402B (zh) * 2011-12-13 2022-04-29 皮里斯制药有限公司 通过抑制il-4和/或il-13与其各自的受体结合来预防或治疗某些障碍的方法
RU2723034C2 (ru) 2014-05-22 2020-06-08 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Новые полипептиды со специфическим связыванием и пути их применения
AU2016293101B2 (en) 2015-07-15 2022-06-16 Pieris Pharmaceuticals Gmbh Novel proteins specific for LAG-3
CN113372446A (zh) * 2016-06-08 2021-09-10 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
JP7225116B2 (ja) 2017-01-18 2023-02-20 ピエリス ファーマシューティカルズ ゲーエムベーハー Ｌａｇ－３に対する結合親和性を有するリポカリンムテイン
AU2018254542B2 (en) * 2017-04-21 2022-12-22 Elanco Us Inc. IL4/IL13 receptor molecule for veterinary use
CN110746507B (zh) * 2018-12-25 2020-06-26 江苏荃信生物医药有限公司 抗人白介素4受体α单克隆抗体及其应用
CA3127973A1 (en) * 2019-03-29 2020-10-08 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
MA55490A (fr) * 2019-03-29 2022-02-09 Astrazeneca Ab Mutéine de lipocaline pour le traitement de l'asthme
IL303729A (en) 2020-12-18 2023-08-01 Astrazeneca Ab Lipocalin mutein dry powder formulation for treatment of asthma
CN115414467B (zh) * 2022-10-14 2023-06-06 中国人民解放军陆军军医大学第二附属医院 载脂蛋白d在制备治疗脑出血药物中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008015239A2 (en) * 2006-08-01 2008-02-07 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
DE4425255A1 (de) 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6446467B1 (en) 1997-07-29 2002-09-10 Physical Optics Corporation Monolithic glass light shaping diffuser and method for its production
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
NZ508249A (en) 1998-06-08 2003-02-28 F Use of PEG-IFN-alpha conjugates in association with ribavirin for the treatment of chronic hepatitis C
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
DE10043509A1 (de) 2000-09-01 2002-03-14 Asta Medica Ag Feste Peptidzubereitungen für die Inhalation und deren Herstellung
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
CA2464690A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
WO2003099207A2 (en) * 2002-05-24 2003-12-04 Agennix Incorporated Oral lactoferrin in the treatment of respiratory disorders
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
RU2389796C2 (ru) 2003-08-29 2010-05-20 Аэровэнс, Инк. Модифицированный антагонист рецептора il-4 и предназначенный для его получения очищенный полинуклеотид
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
CA2622441A1 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
WO2007107563A2 (en) 2006-03-20 2007-09-27 Technische Universität München Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4
WO2009009775A1 (en) * 2007-07-11 2009-01-15 Aerovance, Inc. Pharmaceutical polypeptide dry powder aerosol formulation and method of preparation
HUE043835T2 (hu) 2010-06-08 2019-09-30 Pieris Pharmaceuticals Gmbh IL-4 receptor-alfát kötõ könny-lipokalin muteinek
CN109432402B (zh) * 2011-12-13 2022-04-29 皮里斯制药有限公司 通过抑制il-4和/或il-13与其各自的受体结合来预防或治疗某些障碍的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008015239A2 (en) * 2006-08-01 2008-02-07 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Next generation therapeutics for the treatment of respiratory diseases-dscovery and characterization of an inhalable highly potent and specific anti-IL-4Ra small protein antagonist;HOHLBAUM A.M.等;《INFLAMMATION RESEARCH》;20110630;第60卷(第1期);82-83 *
Non-immunoglobulin based protein scaffolds;John Lfblom等;《CURRNET OPINION IN BIOTECHNOLOGY》;20110602;第22卷(第6期);843-848 *

Also Published As

Publication number Publication date
EP3453400A1 (en) 2019-03-13
CA2858962C (en) 2023-09-05
US9572863B2 (en) 2017-02-21
JP2022084854A (ja) 2022-06-07
PL3453400T3 (pl) 2021-08-09
US20190030121A1 (en) 2019-01-31
AU2012350660A1 (en) 2014-07-03
HUE042720T2 (hu) 2019-07-29
US11382951B2 (en) 2022-07-12
US20200009223A1 (en) 2020-01-09
CN103998053A (zh) 2014-08-20
JP2015505303A (ja) 2015-02-19
JP2017149733A (ja) 2017-08-31
EP2790719A1 (en) 2014-10-22
TR201901826T4 (tr) 2019-03-21
JP6163162B2 (ja) 2017-07-12
US20140357548A1 (en) 2014-12-04
WO2013087660A1 (en) 2013-06-20
JP6725447B2 (ja) 2020-07-15
US10016483B2 (en) 2018-07-10
CN109432402B (zh) 2022-04-29
CA2858962A1 (en) 2013-06-20
US20170112900A1 (en) 2017-04-27
CN103998053B (zh) 2018-11-02
US20210145934A1 (en) 2021-05-20
PL2790719T3 (pl) 2019-05-31
JP2020164532A (ja) 2020-10-08
DK3453400T3 (da) 2021-04-06
SG11201402992SA (en) 2014-07-30
US20230021168A1 (en) 2023-01-19
CN109432402A (zh) 2019-03-08
HUE054342T2 (hu) 2021-08-30
EP3453400B1 (en) 2021-01-20
EP3842058A1 (en) 2021-06-30
ES2710384T3 (es) 2019-04-24
SG10201604566QA (en) 2016-07-28
JP6889201B2 (ja) 2021-06-18
ES2863410T3 (es) 2021-10-11
JP7441589B2 (ja) 2024-03-01
JP2019116499A (ja) 2019-07-18
DK2790719T3 (en) 2019-02-11
AU2012350660B2 (en) 2018-01-25
US10857202B2 (en) 2020-12-08
EP2790719B1 (en) 2018-11-21
EP3842058B1 (en) 2023-08-23
US10398754B2 (en) 2019-09-03

Similar Documents

Publication Publication Date Title
JP7441589B2 (ja) Ｉｌ－４および／またはｉｌ－１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法
US9078860B2 (en) VEGF analogs
JP2022526367A (ja) リポカリンムテインの吸入投与
HK40051700A (en) Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
HK40001660B (en) Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
HK40001660A (en) Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
HK40004111B (en) Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
HK40004111A (en) Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
Eliasb et al. Interleukin-13 Antagonism

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Freising, Germany - Stephen Weah

Applicant after: PIERIS PHARMACEUTICALS GmbH

Address before: Freising, Germany - Stephen Weah

Applicant before: Pieris AG

TA01 Transfer of patent application right

Effective date of registration: 20180402

Address after: Freising, Germany - Stephen Weah

Applicant after: PIERIS PHARMACEUTICALS GmbH

Applicant after: Bristol-Myers Squibb Co.

Address before: Freising, Germany - Stephen Weah

Applicant before: PIERIS PHARMACEUTICALS GmbH

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant
CI03 Correction of invention patent
CI03 Correction of invention patent

Correction item: Claims|Description

Correct: Claims 1-40 submitted on May 29, 2020|Paragraphs 1-133 of the specification submitted on May 29, 2020

False: Claims 1-40 submitted on May 24, 2018|13-1 / 2014

Number: 44-02

Page: full text

Volume: 34

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20181102